Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bundibugyo ebolavirus vaccine candidate
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A Bundibugyo ebolavirus vaccine candidate refers to any of several investigational vaccines designed to prevent Ebola disease caused by the Bundibugyo ebolavirus (BDBV). As of mid-2026, the most prominent candidate is Moderna's mRNA-1469, an mRNA-based vaccine encapsulated in lipid nanoparticles that targets the BDBV glycoprotein (GP). This candidate entered Phase 1 clinical trials in Canada in 2026 with support from the Coalition for Epidemic Preparedness Innovations (CEPI). Other notable candidates in the CEPI-supported portfolio include IAVI's recombinant vesicular stomatitis virus-based vaccine (rVSVΔG/BDBV-GP), manufactured by Hilleman Laboratories, and the University of Oxford/Serum Institute of India's ChAdOx1 BDBV viral vector vaccine. These programs aim to provide the first approved prevention method for BDBV, for which no vaccines or treatments currently exist.
- Other names
- Bundibugyo ebolavirus vaccinemRNA-based Bundibugyo ebolavirus vaccine candidate
02
Targets
BDBV GP (Bundibugyo ebolavirus glycoprotein)
Beyond the preview
Go deeper on Bundibugyo ebolavirus vaccine candidate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bundibugyo ebolavirus vaccine candidate.